Effects of prolactin on platelet activation and blood clotting

References

• Wallaschofski H, Kobsar A, Sokolova O, Eigenthaler M, Lohmann T. Co-activation of platelets by prolactin or leptin – pathophysiological findings and clinical implications. Horm Metab Res 2004;36:1–6.
   PubMed Web of Science ®Google Scholar
• James A. Practice bulletin no. 123: thromboembolism in pregnancy. Obstet Gynecol 2011;118:718–29.
   PubMed Web of Science ®Google Scholar
• Wallaschofski H, Eigenthaler M, Kiefer M, Donne M, Hentschel B, Gertz HJ, Lohmann T. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol 2003;23:479–83.
   PubMed Web of Science ®Google Scholar
• Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000;356:1219–23.
   PubMed Web of Science ®Google Scholar
• Raaz D, Wallaschofski H, Stumpf C, Yilmaz A, Cicha I, Klinghammer L, Daniel WG, Lohmann T, Garlichs CD. Increased prolactin in acute coronary syndromes as putative Co-activator of ADP-stimulated P-selectin expression. Horm Metab Res 2006;38:767–72.
   PubMed Web of Science ®Google Scholar
• Wallaschofski H, Lohmann T, Hild E, Kobsar A, Siegemund A, Spilcke-Liss E, Hentschel B, Stumpf C, Daniel WG, Garlichs CD, Eigenthaler M. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost 2006;96:38–44.
   PubMed Web of Science ®Google Scholar
• Wallaschofski H, Donne M, Eigenthaler M, Hentschel B, Faber R, Stepan H, Koksch M, Lohmann T. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 2001;86:5912–9.
   PubMed Web of Science ®Google Scholar
• Wallaschofski H, Kobsar A, Koksch M, Siegemund A, Hentschel B, Tuschy U, Lohmann T, Sokolova O, Eigenthaler M. Prolactin receptor signaling during platelet activation. Horm Metab Res 2003;35:228–35.
   PubMed Web of Science ®Google Scholar
• Reuwer AQ, Nieuwland R, Fernandez I, Goffin V, van Tiel CM, Schaap MC, Berckmans RJ, Kastelein JJ, Twickler MT. Prolactin does not affect human platelet aggregation or secretion. Thromb Haemost 2009;101:1119–27.
   PubMed Web of Science ®Google Scholar
• Hattori N, Ishihara T, Saiki Y. Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers. Clin Endocrinol (Oxf) 2009;71:702–8.
   PubMed Web of Science ®Google Scholar
• Landberg E, Dahlstrom U, Alehagen U. Serum prolactin and macroprolactin in heart failure: no relation to established laboratory or clinical parameters. Ann Clin Biochem 2011;48:51–6.
   PubMed Web of Science ®Google Scholar
• Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 2005;62:633–43.
   PubMed Web of Science ®Google Scholar
• Hattori N. Macroprolactinemia: a new cause of hyperprolactinemia. J Pharmacol Sci 2003;92:171–7.
   PubMed Web of Science ®Google Scholar
• Anaforoglu I, Ertorer ME, Kozanoglu I, Unal B, Haydardedeoglu FE, Bakiner O, Bozkirli E, Tutuncu NB, Demirag NG. Macroprolactinemia, like hyperprolactinemia, may promote platelet activation. Endocrine 2010;37: 294–300.
   PubMed Web of Science ®Google Scholar
• Khurana S, Liby K, Buckley AR, Ben-Jonathan N. Proteolysis of human prolactin: resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin. Endocrinology 1999;140:4127–32.
   PubMed Web of Science ®Google Scholar
• Ranby M, Ramstrom S, Svensson PO, Lindahl TL. Clotting time by free oscillation rheometry and visual inspection and a viscoelastic description of the clotting phenomenon. Scand J Clin Lab Invest 2003;63:397–406.
   PubMed Web of Science ®Google Scholar
• Lindahl TL, Festin R, Larsson A. Studies of fibrinogen binding to platelets by flow cytometry: an improved method for studies of platelet activation. Thromb Haemost 1992;68:221–5.
   PubMed Web of Science ®Google Scholar
• Lundahl TH, Lindahl TL, Fagerberg IH, Egberg N, Bunescu A, Larsson A. Activated platelets and impaired platelet function in intensive care patients analyzed by flow cytometry. Blood Coagul Fibrinolysis 1996;7:218–20.
   PubMed Web of Science ®Google Scholar
• Morton LF, Hargreaves PG, Farndale RW, Young RD, Barnes MJ. Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity. Biochem J 1995;306 (Pt 2):337–44.
   PubMedGoogle Scholar
• Tynngard N, Lindahl TL, Ramstrom S, Raf T, Rugarn O, Berlin G. Free oscillation rheometry detects changes in clot properties in pregnancy and thrombocytopenia. Platelets 2008;19:373–8.
   PubMed Web of Science ®Google Scholar
• Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19:225–68.
   PubMed Web of Science ®Google Scholar
• Di Cera E. Thrombin as procoagulant and anticoagulant. J Thromb Haemost 2007;5(Suppl. 1):196–202.
   PubMedGoogle Scholar
• May JA, Fox S, Glenn J, Craxford S, Heptinstall S. Platelet function reduces significantly during the morning. Platelets 2008;19:556–8.
   PubMed Web of Science ®Google Scholar
• Bouman HJ, van Werkum JW, Hackeng CM, Verheugt FW, Ten Berg JM. The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin. J Thromb Haemost 2008;6:1040–2.
   PubMed Web of Science ®Google Scholar
• Labarthe B, Theroux P, Angioi M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005;46:638–45.
   PubMed Web of Science ®Google Scholar